How Much Does Enclomiphene Citrate Cost in North Dakota in 2026?

What Enclomiphene Citrate Actually Costs in North Dakota Right Now

The short answer: expect to pay around $90 per month for compounded enclomiphene citrate from a licensed 503A pharmacy serving North Dakota patients. That figure reflects 2026 cash-pay pricing for a standard 25 mg daily oral capsule supply.

Because no FDA-approved enclomiphene product has reached the U.S. market as of May 2026, there is no manufacturer list price, no wholesale acquisition cost (WAC), and no pharmacy benefit manager (PBM) contracted rate. The compound itself is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that raises endogenous testosterone by blocking hypothalamic estrogen feedback 1. In a 2016 study by Kim et al. published in BJU International, enclomiphene 25 mg daily raised total testosterone from a mean baseline of 228 ng/dL to 445 ng/dL at 12 weeks in men with secondary hypogonadism (N=73), an increase of roughly 95% 1. That kind of clinical efficacy drives growing demand, yet the absence of a branded product keeps pricing entirely within the compounding pharmacy channel.

Pricing can vary by $20 to $40 per month depending on the specific 503A pharmacy, capsule strength, and whether the prescription is dispensed as a 30-day or 90-day supply. Ordering a 90-day supply often brings the effective monthly cost down to $70 to $80.

Why There Is No Retail Pharmacy Price in North Dakota

North Dakota's roughly 130 retail chain and independent pharmacies cannot stock enclomiphene citrate as a commercially manufactured drug because no NDA has been approved by the FDA. The drug's development history explains the gap.

Repros Therapeutics (later acquired by Allergan) completed Phase III trials demonstrating that enclomiphene raised testosterone while preserving spermatogenesis, a significant advantage over exogenous testosterone replacement therapy (TRT). The FDA issued a Complete Response Letter in 2015 requesting additional data, and subsequent corporate acquisitions stalled the approval pathway. As of 2026, no sponsor has resubmitted an NDA 2.

This regulatory status means every enclomiphene prescription in North Dakota (and nationally) is filled by compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound patient-specific prescriptions based on valid prescriber orders. The FDA's compounding framework permits this practice provided the pharmacy holds appropriate state licensure and the drug is not "essentially a copy" of a commercially available product. Since no commercial enclomiphene product exists, 503A compounding is straightforward.

North Dakota Medicaid and Enclomiphene Coverage

North Dakota Medicaid does not cover enclomiphene citrate. Period. The program's formulary requires FDA approval as a baseline for drug coverage, and no exception pathway applies here.

North Dakota's Medicaid program, administered by the Department of Health and Human Services, covers approximately 90,000 beneficiaries statewide. The preferred drug list (PDL) includes clomiphene citrate (the racemic mixture sold as Clomid) for female infertility indications, but that coverage does not extend to the isolated trans-isomer compounded for male hypogonadism. Even if a provider submits a prior authorization request for enclomiphene, the absence of an FDA-approved labeling code (NDC) makes adjudication through the pharmacy benefit impossible.

Medicaid beneficiaries seeking testosterone optimization have alternative covered options. The Endocrine Society's 2018 guidelines recommend testosterone cypionate injections (200 mg every 2 weeks, approximate Medicaid cost $30 to $50 per month) as first-line therapy for confirmed hypogonadism 3. The trade-off is that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis and impairs spermatogenesis, making it a poor fit for men planning future fertility.

Commercial Insurance Coverage in North Dakota

Most commercial plans in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, do not cover compounded enclomiphene citrate. The reason mirrors Medicaid: no FDA approval, no NDC, no formulary listing.

A small number of employer-sponsored plans with compounding pharmacy benefits may reimburse part of the cost. This is uncommon. The typical path involves submitting an out-of-network pharmacy claim with the compound's ingredients listed, which requires the prescriber to provide a Letter of Medical Necessity (LMN) documenting the diagnosis of secondary hypogonadism and the clinical rationale for choosing enclomiphene over injectable testosterone. Success rates for these appeals remain low, estimated at 10% to 15% based on industry surveys of compounding pharmacy claims data.

Patients with Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) can use those pre-tax dollars to pay for compounded enclomiphene, since it is a prescribed medication. A valid prescription and pharmacy receipt are sufficient documentation for HSA/FSA reimbursement under IRS Publication 502 guidelines.

Compounded Enclomiphene: How 503A Pharmacies Work in North Dakota

North Dakota licenses compounding pharmacies through the North Dakota Board of Pharmacy. A 503A pharmacy must compound each prescription for an individual patient based on a prescriber's order. Bulk manufacturing without patient-specific prescriptions falls under 503B (outsourcing facility) rules and requires FDA registration.

Several 503A pharmacies with North Dakota dispensing licenses compound enclomiphene citrate. These include both in-state pharmacies and out-of-state pharmacies licensed to ship into North Dakota. Common formulations include:

• 12.5 mg oral capsules (typical starting dose)
• 25 mg oral capsules (standard maintenance dose)
• 50 mg oral capsules (less common, used in select cases)

Quality varies between compounding pharmacies. The Pharmacy Compounding Accreditation Board (PCAB), a service of the Accreditation Commission for Health Care, provides voluntary accreditation. Patients should verify that their compounding pharmacy holds PCAB accreditation or equivalent third-party quality certification, as this indicates adherence to USP <795> standards for non-sterile compounding.

Pricing at $90 per month typically includes the active pharmaceutical ingredient (API), capsule formulation, dispensing, and standard shipping. Some pharmacies charge separately for shipping ($5 to $15), which can affect total monthly cost.

Telehealth Prescribing of Enclomiphene in North Dakota

North Dakota permits telehealth prescribing of enclomiphene citrate. The state's telehealth laws, updated through 2024 legislative sessions, allow licensed prescribers to establish a patient-provider relationship via synchronous audio-video encounters and prescribe Schedule IV and non-scheduled medications without an in-person visit.

Enclomiphene citrate is not a DEA-scheduled substance, so it faces no additional telehealth prescribing restrictions. A physician or advanced practice provider licensed in North Dakota (or holding a compact license recognized by the state) can evaluate a patient via video, order confirmatory bloodwork (total testosterone, LH, FSH, estradiol), review results, and prescribe compounded enclomiphene, all without requiring an office visit.

Multiple telehealth platforms now serve North Dakota patients for hormone optimization. Pricing through telehealth clinics typically bundles the consultation fee ($99 to $199 for initial evaluation) with ongoing medication costs. Some clinics include quarterly lab monitoring in their subscription model. Total monthly cost through a bundled telehealth program ranges from $120 to $200, which includes the provider visit, labs, and medication.

The Endocrine Society's clinical practice guidelines note that secondary hypogonadism diagnosis requires two morning total testosterone measurements below 300 ng/dL, confirmed by appropriately timed lab draws 3. Telehealth providers should follow this same diagnostic standard. A single low testosterone reading is insufficient for diagnosis.

How Enclomiphene Compares to Other Testosterone Optimization Costs in North Dakota

Placing enclomiphene's $90 monthly cost in context requires comparing it to alternative therapies available in North Dakota.

Testosterone cypionate injections (200 mg/mL, 10 mL vial): $30 to $80 per month at North Dakota retail pharmacies using GoodRx-type discount cards. This is the cheapest option but suppresses spermatogenesis and requires intramuscular injection every 1 to 2 weeks. A 2020 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that exogenous testosterone reduced sperm concentration to <1 million/mL in 65% of men within 6 months 4.

Clomiphene citrate (Clomid) (25 to 50 mg daily, off-label for male hypogonadism): $10 to $30 per month generic. The racemic mixture contains both zuclomiphene (cis-isomer) and enclomiphene (trans-isomer). Zuclomiphene has a longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and accumulates over weeks, which may contribute to estrogen agonist side effects including visual disturbances and mood changes 1.

Anastrozole (1 mg, off-label): $10 to $20 per month generic. Sometimes used as monotherapy or adjunct for elevated estradiol but lacks direct testosterone-raising efficacy as a primary agent. The Endocrine Society's 2018 guidelines recommend against aromatase inhibitor monotherapy for hypogonadism treatment.

Nasal testosterone (Natesto): $500 to $700 per month. FDA-approved but expensive and requires three-times-daily dosing. May have less HPG axis suppression than injectable testosterone due to pulsatile delivery, though data are limited.

Enclomiphene at $90 per month sits in a middle price tier. It costs more than generic clomiphene but avoids zuclomiphene accumulation. It costs more than injectable testosterone but preserves fertility. For men under 50 who want both testosterone optimization and spermatogenesis preservation, enclomiphene may offer the best value per clinical outcome.

Discount Programs and Savings Strategies for North Dakota Patients

No manufacturer copay card exists for enclomiphene because no manufacturer markets it. Savings come from other channels.

Compounding pharmacy discount programs: Some national compounding networks offer subscription pricing that reduces the per-month cost to $60 to $75 when patients commit to a 6-month or 12-month supply. Ask the pharmacy directly about auto-refill discounts.

Telehealth clinic bundles: As noted above, several men's health telehealth platforms bundle medication, labs, and consultations for $120 to $200 per month. If you would otherwise pay $90 for medication plus $50 for labs plus $99 for a visit, the bundle creates net savings over time.

HSA/FSA accounts: Using pre-tax dollars effectively reduces cost by 22% to 37% depending on your marginal tax bracket. A patient in the 24% federal bracket paying $90 per month effectively pays $68 after tax savings.

90-day supply orders: Ordering three months at once from a compounding pharmacy typically saves 10% to 15% versus monthly refills, bringing the effective cost closer to $75 to $80 per month.

Comparison shopping: Prices vary meaningfully between compounding pharmacies. Patients should request quotes from at least three licensed 503A pharmacies before committing. Verify each pharmacy's North Dakota dispensing license through the North Dakota Board of Pharmacy license lookup tool.

What North Dakota Patients Should Know Before Starting Enclomiphene

Enclomiphene citrate requires a prescription and baseline lab work. No legitimate pharmacy, compounding or otherwise, should dispense it without a valid prescriber order.

Recommended baseline labs before starting enclomiphene include: total testosterone (drawn between 7:00 and 10:00 AM, fasting), free testosterone, LH, FSH, estradiol, complete blood count (CBC), and comprehensive metabolic panel (CMP) 3. Follow-up labs at 6 to 8 weeks after initiation should include the same hormone panel to assess response and guide dose titration.

Side effects in clinical trials were generally mild. Kim et al. reported headache (5.4%), hot flashes (3.2%), and nasopharyngitis (2.7%) as the most common adverse events at the 25 mg daily dose 1. Visual disturbances, a known concern with racemic clomiphene, occurred at lower rates with the isolated trans-isomer, though the difference did not reach statistical significance in the Phase III dataset (2.1% enclomiphene vs. 1.8% placebo).

Men with primary hypogonadism (testicular failure with elevated LH/FSH) will not respond to enclomiphene. The drug works by stimulating the pituitary to release more LH and FSH, which then signal the testes to produce testosterone. If testicular function is already compromised, this mechanism fails. Diagnostic confirmation of secondary (central) hypogonadism, with low testosterone and low or inappropriately normal gonadotropins, is necessary before prescribing 3.

The Regulatory Outlook and What It Means for Future Pricing

The FDA's 2015 Complete Response Letter to Repros Therapeutics did not reject enclomiphene outright. It requested additional clinical pharmacology data and clarification of the drug's estrogen agonist/antagonist profile in different tissues 2. Corporate changes (Repros was acquired by Allergan, which was then acquired by AbbVie) shifted development priorities away from resubmission.

If an NDA is eventually approved, pricing dynamics would change significantly. A branded product could enter pharmacy formularies, enabling insurance coverage and PBM negotiation. Manufacturer pricing for branded SERMs historically ranges from $200 to $500 per month (for reference, branded Clomid was priced at approximately $400 per month before generic entry). An FDA-approved enclomiphene product at $300 per month with 80% insurance coverage would result in a $60 copay, potentially cheaper than today's $90 compounded cash-pay price.

Conversely, FDA approval could restrict 503A compounding of enclomiphene if the approved product is deemed "commercially available," which is one of the conditions under which compounding of a copy is prohibited. This scenario would eliminate the current $90 compounding option and force patients onto the branded product or its eventual generics.

For now, no NDA resubmission is publicly scheduled. North Dakota patients should plan on the current compounding pricing model for the foreseeable future.